A Phase II Trial Of STI571 For The Treatment Of Platinum And Taxane Refractory Stage III And IV Epithelial Ovarian Cancer And Primary Peritoneal Cancer
I. Determine the response rates (confirmed, complete, and partial) in patients with
platinum- and taxane-refractory stage III or IV ovarian epithelial or primary peritoneal
cancer treated with imatinib mesylate.
II. Determine the toxicity of this drug in these patients. III. Correlate, preliminarily,
CD117 and platelet-derived growth factor receptor expression levels with response in
patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral imatinib mesylate once daily in the absence of disease progression or
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate (complete and partial confirmed response)
Up to 3 years
Southwest Oncology Group
United States: Food and Drug Administration
|Southwest Oncology Group (SWOG) Research Base||San Antonio, Texas 78245|